Mode
Text Size
Log in / Sign up
N/A N=160 Randomized Single-blind Treatment

A Clinical Evaluation of PROPEL® Contour Sinus Implant

Chronic Rhinosinusitis (Diagnosis)

Enrolled (actual)
160
Serious AEs
1.3%
Results posted
Apr 2023
Primary outcome: Primary: Difference in FSO Patency by Blinded Reviewer — 16.54; 12.36 mm^2 — p=0.059

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PROPEL Contour Sinus Implant (Device); Balloon Sinus Dilation Alone (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Intersect ENT
Primary completion
Feb 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in FSO Patency by Blinded Reviewer
16.54; 12.36 0.059
SECONDARY
FSO Cross-sectional Area Change From Baseline on CT by an Independent, Blinded Reviewer
2.63; 1.15; 3.20; 5.95 0.328
SECONDARY
CT Frontal Sinus Outflow Tract (FSOT) Volume by Blinded Reviewer
383.11; 332.17; 386.86; 414.30 0.306
SECONDARY
CT FSO Minimum Diameter by Blinded Reviewer
2.38; 1.89; 2.56; 2.54 0.031 sig
SECONDARY
CT Zinreich's Modified Lund-Mackay Score for the Frontal Sinus by Blinded Reviewer
1.23; 1.28; 1.22; 1.05 0.715
SECONDARY
Number of Sinus Sides Requiring Post-operative Intervention by Clinical Investigators
5; 5; 14; 17; 12; 16 1.00
SECONDARY
CT Cross-sectional Area of FSO by Blinded Reviewer
17.72; 17.81 0.971
SECONDARY
CT Lund-Mackay Score for the Frontal Sinus by Blinded Reviewer
0.77; 0.77; 0.72; 0.67 1.00
SECONDARY
CT Lund-Mackay Score for the Frontal Sinus by Clinical Investigators
0.59; 0.68; 0.53; 0.59 0.225
SECONDARY
Adhesion/Scarring Grade in the Frontal Recess/FSO by Clinical Investigators
0.37; 0.41; 0.30; 0.48; 0.21; 0.48 0.537
SECONDARY
Inflammation Score in the Frontal Recess/FSO by Clinical Investigators
25.94; 28.85; 19.17; 26.67; 21.97; 28.62 0.634
SECONDARY
Polypoid Edema in the Frontal Recess/FSO by Clinical Investigators
0.63; 0.88; 0.53; 0.77; 0.53; 0.80 0.063
SECONDARY
Adhesion/Scarring Grade in the Ethmoid Sinus by Clinical Investigators
0.28; 0.30; 0.34; 0.35; 0.26; 0.39 0.830
SECONDARY
Polyp Grade in the Ethmoid Sinus by Clinical Investigators
0.29; 0.32; 0.30; 0.34; 0.31; 0.39 0.666
SECONDARY
CRS Side-specific Symptom Score by Subject
6.19; 6.25; 4.75; 4.68; 4.42; 4.42 0.868
SECONDARY
SNOT-22 Score by Subject
17.84; 17.84
SECONDARY
RSI Score by Subject
7.7; 7.7
SECONDARY
Implant Delivery Success by Clinical Investigators
80

Summary

The objective of this study is to evaluate the efficacy of PROPEL Contour placement following an in-office frontal sinus balloon dilation (SBD) in patients with chronic rhinosinusitis (CRS)

Eligibility Criteria

Inclusion Criteria

  • Patient is 18 years of age or older.
  • Patient is willing and able to comply with protocol requirements.
  • Patient has confirmed diagnosis of CRS per International Consensus Statement on Allergy and Rhinology, Rhinosinusitis 2021 (ICAR:RS) guidelines.
  • Bilateral disease in the frontal sinuses (Lund-Mackay CT score of ≥1 on each side) on CT scan within 90 days prior to the baseline.
  • A successfully completed in-office bilateral balloon dilation of the FSO with no complication on either side that, in the opinion of the clinical investigator is amenable for PROPEL Contour Sinus Implant placement in both FSO

Exclusion Criteria

  • Patient has structural obstruction that precludes endoscopic visualization of one or both FSOs prior to implant placement.
  • Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus (grade > 2) unless reduced 30 days prior to the baseline procedure
  • Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or other conditions.
  • Known history of allergy or intolerance to corticosteroids or mometasone furoate.
  • Patients with a known hypersensitivity to lactide, glycolide or caprolactone copolymers.
  • Patients with electronic devices in direct connection to the brain or the nervous system such as implantable neurostimulators (e.g. deep brain stimulation), programmable cerebrospinal fluid (CSF) shunts.
  • Patients with monopolar pacemakers (older designs, with lower resistance to interference) or ICD's (implantable cardioverter defibrillator).
  • Patients with implantable, body worn devices such as insulin pumps.
  • Evidence of purulence coming from paranasal sinuses or ostiomeatal complex.
  • Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue).
  • Active viral illness (e.g., flu, shingles).
  • Use of parenteral or injected steroids (e.g. Kenalog) 30 days prior to the baseline procedure.
  • Use of oral steroids, budesonide or other sinus steroid irrigations/rinses or drops, nebulized steroids administered nasally 14 days prior to baseline procedure.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04858802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search